Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
agent, announced, CDX, criteria, cytarabine, decision, decitabine, demonstrating, efficacy, encouraged, fatal, induce, inflation, LDAC, mature, mechanism, met, partnered, PDX, profile, proposed, protocol, RECIST, reinforced, robust, Solid, suspected, undifferentiated
Removed:
foreign, government, growing, myelodysplastic, organization, pandemic, prepaid, release, resolution, review
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view